Stock Events

Stock Events

Nuvectis Pharma 

$23.06
15
+$0.33+1.45% Tuesday 20:00
+$0.00+0%Tuesday 23:30After hours

Statistics

Day High
23.09
Day Low
22.97
52W High
29.28
52W Low
5.55
Volume
5,800
Avg. Volume
-
Mkt Cap
752.77M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.44
-0.37
-0.31
-0.24
Expected EPS
-0.241667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-26.44MNet Income

Analyst Ratings

36.00Average Price Target
The highest estimate is 39.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCT. It's not an investment recommendation.
Meta Platforms
2
META
Palantir Technologies
2
PLTR
Crowdstrike
2
CRWD
Citigroup
2
C

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, making it a direct competitor in the cancer treatment market where Nuvectis Pharma operates.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of cancer therapies, competing directly with Nuvectis Pharma in the oncology sector.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio of oncology drugs and invests heavily in cancer research, positioning it as a competitor to Nuvectis Pharma in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC focuses on the development of new cancer drugs, including targeted therapies, competing with Nuvectis Pharma in the oncology pharmaceuticals market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, directly competing with Nuvectis Pharma in the cancer treatment space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a strong presence in the oncology market with a focus on developing novel cancer treatments, making it a competitor to Nuvectis Pharma.
Rogers
ROG
Mkt Cap2.24B
Roche Holding AG is a major player in oncology, with a wide range of cancer drugs and therapies that compete with Nuvectis Pharma's offerings.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is heavily involved in oncology research and drug development, offering a broad portfolio of cancer treatments that compete with Nuvectis Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is engaged in the development of cancer treatments, including immunotherapies, which positions it as a competitor to Nuvectis Pharma.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company has a growing oncology division focused on developing innovative cancer treatments, competing with Nuvectis Pharma in the pharmaceuticals market.

About

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Show more...
CEO
Ron Bentsur
Employees
13
Country
United States
ISIN
US67080T1088

Listings

XNAS
US
NVCT
BOATS
BOATS
NVCT.BOATS

0 Comments

Share your thoughts

FAQ

What is Nuvectis Pharma stock price today?▼
The current price of NVCT is $23.06 USD — it has increased by +1.45% in the past 24 hours. Watch Nuvectis Pharma stock price performance more closely on the chart.
What is Nuvectis Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Nuvectis Pharma stocks are traded under the ticker NVCT.
Is Nuvectis Pharma stock price growing?▼
NVCT stock has fallen by -7.76% compared to the previous week, the month change is a +7.16% rise, over the last year Nuvectis Pharma has showed a +261.44% increase.
What is Nuvectis Pharma market cap?▼
Today Nuvectis Pharma has the market capitalization of 752.77M
When is the next Nuvectis Pharma earnings date?▼
Nuvectis Pharma is going to release the next earnings report on November 10, 2026.
What were Nuvectis Pharma earnings last quarter?▼
NVCT earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.26 USD resulting in a -14.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nuvectis Pharma revenue for the last year?▼
Nuvectis Pharma revenue for the last year amounts to 0 USD.
What is Nuvectis Pharma net income for the last year?▼
NVCT net income for the last year is -26.44M USD.
How many employees does Nuvectis Pharma have?▼
As of September 02, 2026, the company has 13 employees.
In which sector is Nuvectis Pharma located?▼
Nuvectis Pharma operates in the Health & Wellness sector.
When did Nuvectis Pharma complete a stock split?▼
Nuvectis Pharma has not had any recent stock splits.
Where is Nuvectis Pharma headquartered?▼
Nuvectis Pharma is headquartered in FORT LEE, United States.